Coronavirus mutations in New York, California, cause concern | Science | In-depth report on science and technology | DW

Once health officials began to sequence the positive COVID-19 cases more carefully – that is, by genetically examining the test results – they also found more and more mutations.

Most of these mutations are insignificant. But there are some variants that concern researchers and authorities, in part because they are more contagious and because existing vaccines may be less effective in protecting against them.

A checkpoint at the Czech-German border

There is no more freedom of movement. Some countries are trying to stem the spread of mutations by closing borders.

In addition to the variants identified in Britain, South Africa and Brazil, there are two more variants that cause concern in the United States that appear to have evolved there.

Rapid spread

In November, researchers first noticed a mutation in New York City called B.1.526. Since then, this variant has spread rapidly across the metropolis and across the state. In mid-February, it was detected in 12% of all samples in New York that were sequenced by genes.

This variant also appeared in other countries, such as Denmark.

A woman wearing a face mask is running in front of the bottom of the Golden Gate Bridge

The Californian variant, CAL.20, is believed to be more contagious than the original virus, but not as dangerous as the British variant.

The so-called California variant, first detected in July 2020, has also spread rapidly. Meanwhile, the two similar types, B.1.427 and B.1.429, of the California variant can be found in about a quarter of the samples sequenced by genes in California.

What do we know about the two US variants?

So far, we do not have complete reliable data on these variants. The California variant, CAL.20C, is considered more contagious than the original SARS-CoV-2 virus. In swabs taken from infected individuals, the viral load in the samples was about double. But it is less infectious than the British mutant B.1.1.7, which has now been detected in a large number of countries, including Germany. Existing vaccines are considered to be somewhat less effective against the Californian virus variant, but still sufficient to protect patients from a severe course of COVID-19.

The variant of the New York virus, B.1.526, is similar to the South African variant, B.1.351, which has already been detected in more than 40 countries, and also shows similarity with the Brazilian variants, P.1 and P.2 , which have been detected in more than 20 countries, most recently in the UK.

It is still unclear whether the New York variant is more contagious or dangerous and whether existing vaccines are still sufficiently effective against that variant.

New software helps in search

Finding the respective variants is only possible if you know what to look for. Although we now know the SARS-CoV-2 genome, the virus is 29,903 nucleotides in length, which is too long to allow quick identification of which variants could make it more infectious among the 611,000 genomes now stored in the GISAID database. .

The mutations were found using a new software called Variant Database (VDB) developed at the California Institute of Technology in Pasadena, by a team led by Pamela Bjorkman. It focuses on changes in the peak protein.

A man takes a swab exam in Johannesburg

A mutation called E484K has been found in the South African and Brazilian variants.

The potentially dangerous mutation E484K, which is present in B.1.351 and P.1, alters the receptor binding domain of the spike protein, and it is here that antibodies with the strongest neutralizing effect attack.

A cause for concern, but not for panic

The tip of the spike protein is also altered in the New York variant. Understandably, this has caused some concern, Columbia University epidemiologist Wafaa El-Sadr told the German public broadcaster ARD. “These changes may result in the spike protein being able to bind better. Or that the virus can reproduce more quickly. Or that it cannot be fought by antibodies through our vaccines,” he said.

But until detailed and robust data on U.S. variants is available, these observations remain speculative and there is no need for panic, said Dave Chokshi, commissioner for the New York City Department of Health and Mental Hygiene. So far, there is no evidence that it spreads faster, either by making people sicker or by reducing the vaccine’s effectiveness, he said.

This article was translated from German.

.Source